|
시장보고서
상품코드
2065097
생체 내 CRO 시장 규모, 점유율, 성장 분석 : 서비스 유형별, 모델 유형별, 치료 분야별, 최종사용자별, 용도별, 지역별 - 업계 예측(2026-2033년)In Vivo CRO Market Size, Share, and Growth Analysis, By Service Type (Toxicology Testing, Safety Pharmacology), By Model Type, By Therapeutic Area, By End User, By Application, By Region - Industry Forecast 2026-2033 |
||||||
세계의 생체 내(In Vivo) CRO 시장 규모는 2024년에 53억 달러로 평가되었으며, 2025년 57억 5,000만 달러에서 2033년까지 110억 4,000만 달러로 확대될 전망이며, 예측 기간(2026-2033년) 동안 CAGR 8.5%로 성장할 것으로 전망됩니다.
전 세계 생체 내(in vivo) 계약 연구 기관(CRO) 시장은 전임상 개발 및 독성 평가에 필수적인, 동물 및 생물체를 활용한 연구의 외부 위탁에 중점을 두고 있습니다. 규제 당국과 후원사는 위험을 완화하고 프로젝트 일정에 영향을 미치는 중요한 의사결정을 내리기 위해 생체 내 데이터에 의존하고 있습니다. 이 시장은 학술 기관과의 공동 연구를 바탕으로 GLP 기준을 준수하는 전문적인 다국적 CRO로 발전해 왔으며, 종양학 분야의 이종이식 모델 및 트랜스제닉 서비스 등의 분야에서 성장을 보이고 있습니다. 치료법의 복잡성이 증가함에 따라 신뢰성이 높은 중개 연구 데이터에 대한 수요가 높아지고 있으며, 각 CRO 기업들은 고도의 인간화 마우스 모델이나 비설치류를 활용한 연구 등 제공 서비스를 확대하고 있습니다. 또한, AI는 시험 설계의 최적화, 프로세스의 자동화, 예측 모델링의 개선을 통해 시험 효율을 대폭 향상시키고, 데이터 분석의 신속화와 후보 화합물의 검증 강화를 이끌어내며, 궁극적으로 연구 워크플로우의 효율화를 실현하고 있습니다.
전 세계 생체 내 CRO 시장의 성장요인
전 세계 생체 내 CRO 시장은 전문적인 기술과 복잡한 생체 내 모델에 대한 접근성을 제공하는 계약 연구 기관(CRO)의 영향을 크게 받고 있습니다. 이를 통해 후원 기업은 사내에 막대한 자원을 투입하지 않고도 기술력을 강화할 수 있게 됩니다. 이러한 아웃소싱은 프로젝트의 시작을 가속화하고 자원 활용을 최적화합니다. 이를 통해 조직은 외부의 전문 지식과 규제 관련 인사이트를 활용하면서도 신약 개발 과정에 집중할 수 있게 됩니다. 업무상의 부담을 줄임으로써, 아웃소싱은 스폰서의 자본 지출을 절감하고 업무상의 위험을 낮춥니다. 이에 따라 아웃소싱된 생체 내 서비스는 업계 내 지속적인 성장을 촉진하는 매력적인 대안으로서의 입지를 확고히 하고 있습니다.
전 세계 생체 내(in vivo) CRO 시장의 제약요인
지역마다 다른 규제 요건은 규정 준수 측면에서 중대한 과제를 야기하며, 시험의 적시 개시를 방해하거나 국제 프로젝트를 복잡하게 만들어 시장 성장을 저해하는 요인이 됩니다. 이러한 다양한 승인 절차에 더해, 동물 복지 기준이나 보고 프로토콜의 차이로 인해 막대한 행정적 노력이 필요한 경우가 많으며, 그 결과 프로젝트 일정이 장기화됩니다. 이러한 복잡한 상황은 위험 증가에 대한 우려가 제기됨에 따라, 발주자나 계약연구기관(CRO)이 특정 프로그램의 외주를 주저하게 만드는 요인이 될 가능성이 있습니다. 또한, 전문적인 규제 지식에 대한 수요가 높아짐에 따라 사업 운영의 유연성이 제한되어 소규모 사업자들이 국제적인 서비스 제공 범위를 확대하는 것을 주저하게 될 가능성이 있으며, 그 결과 시장 전체의 발전이 둔화될 우려가 있습니다.
전 세계 인 비보 CRO 시장의 동향
전 세계 생체 내 CRO 시장에서는 표적 검증, 바이오마커 발견, 전임상 단계의 개념 증명 등 다양한 연구 단계를 원활하게 연결하는 통합적인 트랜스레이셔널 서비스로의 추세가 강화되고 있습니다. 각 스폰서사는 의사결정 과정을 강화하고 프로그램의 위험을 줄이기 위해 맞춤형 질환 모델, 첨단 생체 내 영상 기술, 종합적인 바이오분석, 그리고 일관된 데이터 통합을 제공하는 CRO와의 제휴를 모색하고 있습니다. 이러한 동향은 보다 긴밀한 과학적 협력을 촉진하고 모듈식 서비스 제공을 가능하게 하며, CRO를 단순한 서비스 제공업체가 아닌, 임상 가설에 부합하는 귀중한 생물학적 인사이트를 제공하고 프로그램 개발의 전반적인 진척을 지원할 수 있는 전략적 파트너로 자리매김하고 있습니다.
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 생체 내 CRO 시장 규모 : 서비스 유형별
세계의 생체 내 CRO 시장 규모 : 모델 유형별
세계의 생체 내 CRO 시장 규모 : 치료 분야별
세계의 생체 내 CRO 시장 규모 : 최종사용자별
세계의 생체 내 CRO 시장 규모 : 용도별
세계의 생체 내 CRO 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSMGlobal In Vivo Cro Market size was valued at USD 5.3 Billion in 2024 and is poised to grow from USD 5.75 Billion in 2025 to USD 11.04 Billion by 2033, growing at a CAGR of 8.5% during the forecast period (2026-2033).
The global in vivo contract research organization (CRO) market focuses on outsourced animal and whole organism studies essential for preclinical development and toxicology assessments. Regulators and sponsors rely on in vivo data to mitigate risks and inform critical decisions, impacting project timelines. The market has evolved from academic collaborations to specialized multinational CROs that adhere to GLP standards, with growth in areas such as oncology xenografts and transgenic services. Increasing therapeutic complexity drives demand for reliable translational data, prompting CROs to enhance their offerings, including advanced humanized mouse models and non-rodent species studies. Moreover, AI significantly boosts trial efficiency by optimizing study design, automating processes, and improving predictive modeling, resulting in faster data analysis and enhanced candidate validation, ultimately streamlining research workflows.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global In Vivo Cro market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global In Vivo Cro Market Segments Analysis
Global in vivo cro market is segmented by service type, model type, therapeutic area, end user, application and region. Based on service type, the market is segmented into Toxicology Testing, Safety Pharmacology, Pharmacokinetics & Pharmacodynamics (PK/PD) Studies, Efficacy Studies, Bioanalysis Services and Others. Based on model type, the market is segmented into Rodent Models, Non-Rodent Models, Disease Models, Genetically Engineered Models and Others. Based on therapeutic area, the market is segmented into Oncology, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders, Metabolic Disorders and Others. Based on end user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Academic & Research Institutes, Medical Device Companies and Others. Based on application, the market is segmented into Drug Discovery, Preclinical Testing, Translational Research, Biomarker Development and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global In Vivo Cro Market
The Global In Vivo Cro market is significantly influenced by contract research organizations that provide specialized skills and access to complex in vivo models, allowing sponsors to enhance their technical capabilities without the need for extensive internal resources. This outsourcing accelerates project initiation and optimizes resource utilization, enabling organizations to concentrate on essential drug discovery processes while benefiting from external expertise and regulatory knowledge. By alleviating the operational burden, outsourcing reduces capital expenses and mitigates operational risks for sponsors, positioning outsourced in vivo services as a compelling choice that fosters ongoing growth within the industry.
Restraints in the Global In Vivo Cro Market
Variations in regulatory requirements across different regions present significant compliance challenges that can hinder the timely start of studies and complicate international projects, posing obstacles to market growth. These diverse approval processes, along with differing animal welfare standards and reporting protocols, often necessitate substantial administrative effort, thereby extending project timelines. This intricate landscape may discourage sponsors and Contract Research Organizations (CROs) from outsourcing certain programs due to heightened perceived risks. Furthermore, the demand for specialized regulatory knowledge limits operational adaptability and may dissuade smaller providers from broadening their international service offerings, consequently slowing the overall progression of the market.
Market Trends of the Global In Vivo Cro Market
The Global In Vivo CRO market is increasingly trending towards integrated translational services that facilitate seamless connections across various research stages, including target validation, biomarker discovery, and preclinical proof of concept. Sponsors are seeking partnerships with CROs that provide tailored disease models, advanced in vivo imaging, comprehensive bioanalytics, and cohesive data integration to enhance decision-making processes and mitigate program risks. This trend fosters closer scientific collaboration and enables modular service offerings, positioning CROs not just as service providers but as strategic allies capable of delivering valuable biological insights that align with clinical hypotheses and support holistic program development trajectories.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
- Value Chain Analysis
- Case Studies
- Technology Assessment
- Customer & Buying Criteria Analysis
- Pipeline Analysis
- Disease Epidemiology
Global In Vivo CRO Market Size by Service Type & CAGR (2026-2033)
- Market Overview
- Toxicology Testing
- Safety Pharmacology
- Pharmacokinetics & Pharmacodynamics (PK/PD) Studies
- Efficacy Studies
- Bioanalysis Services
- Others
Global In Vivo CRO Market Size by Model Type & CAGR (2026-2033)
- Market Overview
- Rodent Models
- Non-Rodent Models
- Disease Models
- Genetically Engineered Models
- Others
Global In Vivo CRO Market Size by Therapeutic Area & CAGR (2026-2033)
- Market Overview
- Oncology
- Infectious Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Metabolic Disorders
- Others
Global In Vivo CRO Market Size by End User & CAGR (2026-2033)
- Market Overview
- Pharmaceutical Companies
- Biotechnology Companies
- Academic & Research Institutes
- Medical Device Companies
- Others
Global In Vivo CRO Market Size by Application & CAGR (2026-2033)
- Market Overview
- Drug Discovery
- Preclinical Testing
- Translational Research
- Biomarker Development
- Others
Global In Vivo CRO Market Size & CAGR (2026-2033)
- North America (Service Type, Model Type, Therapeutic Area, End User, Application)
- US
- Canada
- Europe (Service Type, Model Type, Therapeutic Area, End User, Application)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Service Type, Model Type, Therapeutic Area, End User, Application)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Service Type, Model Type, Therapeutic Area, End User, Application)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Service Type, Model Type, Therapeutic Area, End User, Application)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Charles River Laboratories International, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Labcorp Drug Development
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- IQVIA Holdings Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ICON plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Evotec SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi AppTec Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pharmaron Beijing Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Scientific SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Covance Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Syneos Health, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Parexel International Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medpace Holdings, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- NAMSA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Frontage Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Crown Bioscience Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- The Jackson Laboratory
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Taconic Biosciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioDuro LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- JOINN Laboratories Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- KCAS Bioanalytical & Biomarker Services LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
